In a significant ruling at the pleading stage, the Delaware Court of Chancery has found a reasonable inference that directors of Footprint International Holdco, Inc. (the "Company") breached their fiduciary duties by approving a substantial financing deal. The court’s decision in Guilbeau v. Footprint (May 11, 2026) also suggests that three institutional investors, referred to as the "Funds," may have aided and abetted these breaches through their designees on the Company’s board. This complex case delves into corporate governance, director duties, and the intricate dynamics of financing in a company facing financial distress.
The financing in question, dubbed the "Financing," involved the issuance of a new class of preferred stock, designated "Class F Stock," to raise $500 million. A significant portion of this capital, $450 million, was provided by three of the Company’s largest stockholders: Cleveland Avenue, Olympus Growth, and Movendo Capital (collectively, the "Funds"). The court’s preliminary finding of potential fiduciary duty breaches by the Company’s directors and complicity by the Funds sets the stage for a potentially protracted legal battle concerning the fairness and propriety of the transaction.
Background: A Company’s Financial Descent and Shifting Control
Footprint International Holdco, Inc., a developer of biodegradable food packaging, embarked on its corporate journey with a Class A preferred stock offering in 2019, raising $90 million from approximately 80 investors, including the plaintiffs in this case. This initial financing round established a Governance Agreement that provided Class A stockholders with favorable liquidation preferences, a prime position in the liquidation waterfall, and the crucial right to appoint a director. Critically, this agreement also stipulated that any alteration to the Class A stock’s rights, powers, or preferences required the approval of a majority of the Board, including the Class A Director.
A pivotal shift occurred in November 2020 when the Company secured an additional $150 million through the sale of Class A stock to the Funds. This transaction necessitated an amendment to the Governance Agreement, with the consent of existing Class A stockholders. The amended agreement reshaped the Board’s composition and expanded the list of actions requiring the Class A Director’s favorable vote. Under this new structure, the Funds were mandated to vote for a slate of ten directors, including three designees from each Fund (the "Fund Designees"), three from ZenCap, the Class A Director, two "Common-Approved Directors" selected by the Board and ratified by common stockholders, and the Company’s CEO. Over the subsequent two years, the Governance Agreement underwent five further amendments, none of which were disclosed to or consented to by the Class A stockholders.
The Company’s financial trajectory took a downturn. In 2021, a proposed merger was mutually terminated due to adverse market conditions. Facing a growing need for capital, the Company obtained $71 million in bridge loans from the Funds. These loans were structured with the option to convert into a new series of Class F preferred stock, foreshadowing the eventual financing structure.
The Financing: A Desperate Measure Amidst Insolvency Concerns
By early 2023, the Company’s financial situation was precarious, with the Board perceiving it as "teetering on insolvency." Recognizing the likelihood of receiving financing proposals from parties affiliated with directors, the Board established a three-member special committee of independent directors (the "Committee") on February 3, 2023, to evaluate any such proposals. The Committee comprised the Class A Director, one of the Common-Approved Directors, and the Company’s Chief Technology Officer (who had transitioned from a Common-Approved Director to a ZenCap Designee). However, the Committee’s authority was limited to making recommendations; the final decision-making power remained with the full Board.
On March 20, 2023, the Funds presented their financing proposal, offering to invest up to $500 million in Class F stock. On the same day, the Committee deemed the proposal fair and recommended its adoption by the Company. This Financing valued the Company at a pre-money valuation of $500 million.
A Trail of Ignored Opportunities and Questionable Deal Terms
The court’s analysis revealed several "seemingly problematic aspects" of the Financing that fueled the plaintiffs’ claims. Notably, the Company allegedly received and largely ignored other financing proposals prior to the Funds’ offer. In January 2023, an investment firm offered $125 million at a $390 million pre-money valuation, a proposal that was not considered. In early March, another offer was received at a $1 billion valuation, which neither the Committee nor the Board pursued. A more complex, albeit verbal, offer emerged on March 27, involving the acquisition of at least 80% of the Company’s equity (including most or all Class A stock) at a $670 million valuation, coupled with an additional $545 million investment and the assumption of $180 million in liabilities. While the Committee acknowledged this proposal’s potential to address the Company’s "severe liquidity position," it rejected the offer, citing a lack of "meaningful return to the Company’s stakeholders." The Board later noted that the investment firm "did not appear [to have] the requisite funds to consummate the transaction," though the basis for this observation was not detailed in the meeting minutes. Crucially, the Committee never engaged in direct communication or negotiation with this firm.
Further complicating the Financing were the "special benefits" provided to the Funds and two other large stockholders, ZenCap and Koch, who possessed "blocking rights." To secure ZenCap’s consent, the Company agreed to use $10 million of the Financing proceeds to redeem ZenCap’s Class B stock and convert its remaining Class B shares into a new series with enhanced liquidation rights. Koch’s consent was obtained by agreeing to use $35 million from the Financing to redeem all of Koch’s Class D shares and by promising additional cash payments or shares in a liquidation event or IPO. When lender consent for the Koch repurchase proved elusive, Cleveland Avenue stepped in to acquire Koch’s shares. In return, the Company agreed to significantly increase the value of those shares, enhancing their original issue price and reducing their conversion price, thereby enabling them to convert into nearly 27 times more common stock upon an IPO.
Disclosure to stockholders also came under scrutiny. In August 2023, the Company provided a notice, subscription agreement, and term sheet for the Financing. The Term Sheet attributed a $500 million pre-money valuation, indicating that Class F stock would constitute 50% of the Company’s equity. A cap table within the Term Sheet projected distributions based on a $1.2 billion liquidity event, revealing that only Class A stockholders would not be made whole, receiving a mere 4% of their original investment. The court noted that the Term Sheet failed to disclose the depressed valuation, the material, non-ratable benefits provided to the Funds, ZenCap, and Koch, and the existence and disregard of other financing proposals.
Ultimately, the Funds subscribed for 90% of the Financing, offering the remaining 10% to other stockholders. The Funds received new Class F stock and exchanged their Class A stock for "Class A-1" shares, which converted into approximately 1.71 times more common stock than the original Class A shares. The Governance Agreement was further amended to strip Class A stockholders of all protections and reduce the Board to four seats, occupied by the three Fund Designees and one Common-Approved Director.
Court’s Rulings: Fiduciary Duties, Entire Fairness, and Aiding and Abetting
The Court of Chancery’s decision addressed several critical legal issues:
1. Control and Fiduciary Duties: The court determined that one of the Funds, despite holding a substantial 26.4% stake, was not a controller of the Company and therefore did not owe direct fiduciary duties. While acknowledging this stake as the most persuasive factor for plaintiffs alleging control, the court found it mitigated by the presence of other large stockholders and the Fund’s obligation under the Governance Agreement to vote for a fixed slate of directors. However, the court’s extensive discussion on how a 26.4% stockholder could be deemed a controller under various circumstances, particularly in light of recent statutory changes defining control based on a one-third voting power threshold, was interpreted as a pointed critique of the new "bright-line rule."
2. Entire Fairness Review: The court concluded that the "entire fairness" standard of review applied to the Financing. This standard, the most rigorous under Delaware law, requires a showing of both fair price and fair dealing. The court found that a majority of the Board lacked independence with respect to the Financing. The three Fund Designees, as executives or principals of the Funds, and one ZenCap Designee, an executive of ZenCap, were deemed not independent due to the material benefits conferred upon the Funds and ZenCap. The court considered the two Common-Approved Directors, the Class A Director, and one non-executive ZenCap Designee to be independent. The CEO-director was also deemed independent, as his independence was not challenged. The crucial determination hinged on the independence of the Company’s Chief Technology Officer, who was also a ZenCap Designee. The court ruled he was not independent, citing his status as a Company officer, his duty to comply with majority board decisions, and his self-interest in the Company’s continued operation, which was contingent on the Financing. Furthermore, the court found the Financing to be coercive to Class A stockholders, thus triggering the entire fairness review on that basis as well.
3. Failure of Entire Fairness: With respect to the merits of the Financing, the court found that the alleged facts supported a reasonable inference that the Financing was not entirely fair. Regarding price, the court noted that contemporaneous transactions and prior bridge loans from the Funds suggested a significantly higher valuation than the $500 million pre-money valuation of the Financing. The court also highlighted that prior proposals in March 2023, including one from the Funds themselves via bridge loans, indicated a $1 billion pre-money valuation. In terms of process, the court identified materially inadequate disclosure to stockholders, as the Term Sheet failed to reveal the depressed valuation, specific benefits to certain parties, and the existence and dismissal of other financing proposals.
4. Aiding and Abetting Claims: The court reiterated its stance that the heightened pleading standard for aiding and abetting claims, recently established by the Delaware Supreme Court in Mindbody and Columbia Pipeline, may not apply when claims are brought against affiliates or advisors of allegedly culpable fiduciaries. These decisions had tightened the "knowing participation" element, requiring "actual" knowledge and "affirmative action" rather than "reckless indifference" or a "conscious failure to act." The court emphasized that these precedents were primarily in the context of third-party acquirers and did not explicitly address claims against affiliates of fiduciaries. In the Guilbeau case, the court argued that the claim was that the Funds executed their scheme "with and through their Board designees," a situation distinct from that of a third-party acquirer.
The court found that the alleged facts supported a reasonable inference that the Funds "knowingly participated" in the directors’ fiduciary breaches. Knowledge was imputed to each Fund through its Board designee, as it was inferable that the designees acted on behalf of their respective Funds. For the Cleveland and Olympus Designees, an agreement between the designee and their employer was easily inferred. For the Movendo Designee, a non-executive director, the court considered him a "dual fiduciary" at the pleading stage, with his knowledge imputable to Movendo. Regarding "participation," the court found it reasonable to infer that the Funds "actively participated in and supported their Board designee’s actions." The court suggested that the Funds formulated a plan to secure approval of the Financing and were present through their designees during Board deliberations. The court dismissed the defendants’ argument of "conclusory allegations" of the Funds being "in cahoots," stating that given the designees’ employee and fiduciary status, the complaint’s allegations supported the inference that the designees approved the Financing to advance the Funds’ interests at the expense of minority stockholders, which was inferably what each Fund intended.
Broader Implications and Future Proceedings
The Guilbeau v. Footprint decision underscores the Delaware Court of Chancery’s continued vigilance in scrutinizing corporate transactions, particularly those involving financially distressed companies and significant investor influence. The ruling highlights the critical importance of robust disclosure, independent board oversight, and fair valuation processes.
The court’s nuanced approach to the "control" definition, even while adhering to the new statutory framework, suggests that fact-specific inquiries will remain central to such analyses. Furthermore, the court’s willingness to potentially apply a less stringent pleading standard for aiding and abetting claims against affiliates of fiduciaries could have significant implications for future litigation, potentially broadening the scope of liability for investors acting through board representation.
The case will now likely proceed to discovery and potentially a trial on the merits, where the parties will have the opportunity to present further evidence and arguments regarding the fairness of the Financing. The outcome will have broader implications for how institutional investors interact with portfolio companies, particularly in moments of financial exigency, and for the duties owed by directors and those who influence them. The decision serves as a potent reminder that even at the pleading stage, allegations of self-dealing, inadequate disclosure, and compromised independence can trigger rigorous judicial review.
